Gyanendra Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gyanendra Singh has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Anurag Singh
Department of Pathology, King George Medical University, Lucknow, India
4 shared publicationsParth Goswami
Department of Pathology, All India Institute of Medical Sciences, Rajkot, Gujarat, India
4 shared publicationsTarang Patel
Department of Pathology, All India Institute of Medical Sciences, Rajkot, Gujarat, India
4 shared publications- Vishal Tayade
Department of Pathology Grant Government Medical College and Sir J. J. Group of Hospitals Mumbai India
4 shared publications - Amit Sonagra
All India Institute of Medical Sciences
3 shared publications - Mehul Kaliya
All India Institute of Medical Sciences
3 shared publications
Latest Publications
- 2 October 2026
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
Interobserver Reproducibility of Treatment-Defining HER2-Low and HER2-Ultralow Immunohistochemical Scoring in Breast Carcinoma: A Systematic Review
Eligibility for trastuzumab deruxtecan now depends on separating HER2 immunohistochemistry (IHC) score 0 from 1+ (HER2-low) and, within score 0, null from ultralow staining—boundaries the assay was not designed to resolve. We systematically identified and appraised studies reporting interobserver or interlaboratory agreement among pathologists for HER2 IHC scoring of breast carcinoma at these contrasts. PubMed/MEDLINE, Scopus, and Web of Science were searched (17 to 18 June 2026) without date or language limits, following a prospectively registered protocol and the PRISMA 2020 guidelines. Two reviewers independently screened records, extracted data verbatim, and appraised quality using QAREL; no values were estimated or imputed. Eighty-nine studies were included: 34 at first submission, and 55 added after an audit of the screening record and retrieval of previously unavailable reports, both completed during revision and disclosed in full. Agreement at the low-end contrasts was consistently lower than for the full HER2 category set: coefficients operationalized directly at 0 versus 1+ ranged from 0.41 to 0.69 across kappa and intraclass-correlation families, per-category coefficients for score 1+ ranged from 0.19 to 0.65, with most below 0.55, and overall multicategory agreement was generally higher (most coefficients 0.43 to 0.85). Agreement for null versus ultralow was examined in 10 of the 89 studies across 4 constructs and was low and spectrum-dependent; in the largest direct examination, per-category κ for ultralow was 0.09 to 0.21. The evidence was fragmented across at least 9 agreement metrics and across binary, per-category, and within-multicategory operationalizations of the same contrast; many studies reported no confidence interval; and no metric family and operationalization was shared by 2 or more studies with a derivable standard error on comparable cohorts. Sixty-two of 89 studies raised some concerns, and 27 were at high risk of bias. Analytical reproducibility at these treatment-defining boundaries is therefore not yet established; the fragmentation that prevents a pooled estimate is itself a finding, underscoring the need for harmonized reporting and analytical validation as priorities.
- 2 October 2026
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
Interobserver Reproducibility of Treatment-Defining HER2-Low and HER2-Ultralow Immunohistochemical Scoring in Breast Carcinoma: A Systematic Review
Eligibility for trastuzumab deruxtecan now depends on separating HER2 immunohistochemistry (IHC) score 0 from 1+ (HER2-low) and, within score 0, null from ultralow staining—boundaries the assay was not designed to resolve. We systematically identified and appraised studies reporting interobserver or interlaboratory agreement among pathologists for HER2 IHC scoring of breast carcinoma at these contrasts. PubMed/MEDLINE, Scopus, and Web of Science were searched (17 to 18 June 2026) without date or language limits, following a prospectively registered protocol and the PRISMA 2020 guidelines. Two reviewers independently screened records, extracted data verbatim, and appraised quality using QAREL; no values were estimated or imputed. Eighty-nine studies were included: 34 at first submission, and 55 added after an audit of the screening record and retrieval of previously unavailable reports, both completed during revision and disclosed in full. Agreement at the low-end contrasts was consistently lower than for the full HER2 category set: coefficients operationalized directly at 0 versus 1+ ranged from 0.41 to 0.69 across kappa and intraclass-correlation families, per-category coefficients for score 1+ ranged from 0.19 to 0.65, with most below 0.55, and overall multicategory agreement was generally higher (most coefficients 0.43 to 0.85). Agreement for null versus ultralow was examined in 10 of the 89 studies across 4 constructs and was low and spectrum-dependent; in the largest direct examination, per-category κ for ultralow was 0.09 to 0.21. The evidence was fragmented across at least 9 agreement metrics and across binary, per-category, and within-multicategory operationalizations of the same contrast; many studies reported no confidence interval; and no metric family and operationalization was shared by 2 or more studies with a derivable standard error on comparable cohorts. Sixty-two of 89 studies raised some concerns, and 27 were at high risk of bias. Analytical reproducibility at these treatment-defining boundaries is therefore not yet established; the fragmentation that prevents a pooled estimate is itself a finding, underscoring the need for harmonized reporting and analytical validation as priorities.
- 2 October 2026
- Published by Wiley in Cancer Cytopathology
- Vol. 134 (10) , e70155
Diagnostic accuracy of methylthioadenosine phosphorylase immunohistochemistry for CDKN2A homozygous deletion and for distinguishing mesothelioma from reactive mesothelial proliferations: A systematic review and bivariate meta‐analysis
Distinguishing mesothelioma from reactive mesothelial proliferations is a recurring problem in serous effusion and small‐biopsy practice, where invasion cannot be assessed and diagnosis rests on cell block immunohistochemistry. Loss of methylthioadenosine phosphorylase (MTAP) immunostaining is an inexpensive surrogate for CDKN2A homozygous deletion; however, its accuracy used alone has not been quantified. This is a systematic review of diagnostic test accuracy studies (PRISMA‐DTA, QUADAS‐2, and Open Science Framework). Four databases were searched to June 18, 2026. Eligible studies reported MTAP immunohistochemistry alone with an extractable 2 × 2 table against CDKN2A homozygous deletion (primary reference) or the integrated mesothelioma‐versus‐reactive diagnosis (secondary). Bivariate/hierarchical summary receiver operating characteristic (HSROC) meta‐analysis used mada, with a prespecified univariate summary where specificity approached 100%. Nineteen studies contributed 21 two‐by‐two tables, five of nine secondary arms being effusion cytology cell blocks. Against CDKN2A homozygous deletion (seven studies), pooled sensitivity was 75.9% (95% CI, 56.6%–88.4%) and specificity was 79.4% (95% CI, 65.8%–88.6%); the area under the HSROC curve (AUC) was 0.845. For mesothelioma versus reactive proliferations (nine pleural arms), pooled sensitivity was 52.0% (95% CI, 44.4%–59.5%), with specificity at or near 100% (bivariate sensitivity, 51.7%; bivariate specificity, 95.5%; AUC, 0.758). Peritoneal data were too sparse to pool (one cohort; sensitivity, 33.3%). Sensitivity did not differ by specimen format (histology, 51.6%; effusion cytology, 52.9%). MTAP immunohistochemistry shows useful but imperfect concordance with CDKN2A homozygous deletion, and high specificity for the mesothelioma‐versus‐reactive distinction. On a cell block or small biopsy, a confident complete‐loss call is essentially specific for malignancy; molecular confirmation by fluorescence in situ hybridization, copy number analysis, or a next‐generation sequencing panel should be retained where MTAP is equivocal or uninterpretable, and for peritoneal disease.
- 2 October 2026
- Published by Wiley in Cancer Cytopathology
- Vol. 134 (10) , e70155
Diagnostic accuracy of methylthioadenosine phosphorylase immunohistochemistry for CDKN2A homozygous deletion and for distinguishing mesothelioma from reactive mesothelial proliferations: A systematic review and bivariate meta‐analysis
Distinguishing mesothelioma from reactive mesothelial proliferations is a recurring problem in serous effusion and small‐biopsy practice, where invasion cannot be assessed and diagnosis rests on cell block immunohistochemistry. Loss of methylthioadenosine phosphorylase (MTAP) immunostaining is an inexpensive surrogate for CDKN2A homozygous deletion; however, its accuracy used alone has not been quantified. This is a systematic review of diagnostic test accuracy studies (PRISMA‐DTA, QUADAS‐2, and Open Science Framework). Four databases were searched to June 18, 2026. Eligible studies reported MTAP immunohistochemistry alone with an extractable 2 × 2 table against CDKN2A homozygous deletion (primary reference) or the integrated mesothelioma‐versus‐reactive diagnosis (secondary). Bivariate/hierarchical summary receiver operating characteristic (HSROC) meta‐analysis used mada, with a prespecified univariate summary where specificity approached 100%. Nineteen studies contributed 21 two‐by‐two tables, five of nine secondary arms being effusion cytology cell blocks. Against CDKN2A homozygous deletion (seven studies), pooled sensitivity was 75.9% (95% CI, 56.6%–88.4%) and specificity was 79.4% (95% CI, 65.8%–88.6%); the area under the HSROC curve (AUC) was 0.845. For mesothelioma versus reactive proliferations (nine pleural arms), pooled sensitivity was 52.0% (95% CI, 44.4%–59.5%), with specificity at or near 100% (bivariate sensitivity, 51.7%; bivariate specificity, 95.5%; AUC, 0.758). Peritoneal data were too sparse to pool (one cohort; sensitivity, 33.3%). Sensitivity did not differ by specimen format (histology, 51.6%; effusion cytology, 52.9%). MTAP immunohistochemistry shows useful but imperfect concordance with CDKN2A homozygous deletion, and high specificity for the mesothelioma‐versus‐reactive distinction. On a cell block or small biopsy, a confident complete‐loss call is essentially specific for malignancy; molecular confirmation by fluorescence in situ hybridization, copy number analysis, or a next‐generation sequencing panel should be retained where MTAP is equivocal or uninterpretable, and for peritoneal disease.
- 2 September 2026
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 20 (12-13) , 759-770
Integrated coagulation, platelet, and UACR profiling in type 2 diabetes microvascular complications: a western India study
1. Diabetes mellitus (DM) is a significant global health issue that afflicts over 537 million adults worldwide, especially type 2 diabetes mellitus (T2DM), which accounts 90% of DM cases [1,2]. Bey...
- 2 September 2026
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 20 (12-13) , 759-770
Integrated coagulation, platelet, and UACR profiling in type 2 diabetes microvascular complications: a western India study
1. Diabetes mellitus (DM) is a significant global health issue that afflicts over 537 million adults worldwide, especially type 2 diabetes mellitus (T2DM), which accounts 90% of DM cases [1,2]. Bey...
- 6 August 2026
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 85, 152703
Diagnostic accuracy of nuclear STAT6 immunohistochemistry for solitary fibrous tumour: a systematic review and meta-analysis
- 6 August 2026
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 85, 152703
Diagnostic accuracy of nuclear STAT6 immunohistochemistry for solitary fibrous tumour: a systematic review and meta-analysis
- Open Access
- 9 July 2026
- Published by Wolters Kluwer Health in Journal of Cytology
- Vol. 43 (3) , 167-173
Diagnostic Efficacy of the International System for Reporting Serous Fluid Cytopathology Classification in Pleural Effusion Samples to Analyze the Risk of Malignancy Associated with Each Category and Explore the Prognostic Significance of the Systemic Immune-Inflammation Index within These Classifications
Background: Pleural effusion is a common clinical manifestation of both neoplastic and nonneoplastic conditions. Cytological evaluation of serous fluids remains a cost-effective and minimally invasive diagnostic tool. To standardize reporting and improve the diagnostic accuracy, the International Academy of Cytopathology and the American Society of Cytopathology proposed the International System for Reporting Serous Fluid Cytopathology (ISRSFC). The Systemic Immune-Inflammation Index (SII) is a composite measure of systemic inflammatory status, being a novel prognostic biomarker. It has been linked to adverse outcomes in several malignancies. This study aimed to evaluate the diagnostic efficacy of the ISRSFC in categorizing pleural effusion samples, determine the risk of malignancy (ROM) for each diagnostic category, and assess the prognostic significance of SII across ISRSFC categories. Materials and Methods: A retrospective cross-sectional study was conducted on 142 pleural effusion cases diagnosed at the All India Institute of Medical Sciences, Rajkot, from January 2023 to April 2025. Cytological samples were classified according to ISRSFC categories and correlated with histopathology, radiology, and clinical data. Complete blood count parameters were retrieved to calculate the SII (neutrophil × platelet/lymphocyte count). Statistical analysis was performed using Statistical Package for the Social Sciences version 23. Results: Of 142 cases, the majority fell into benign categories (2A and 2B, 88%). ROM increased progressively across ISRSFC categories: 0% (Category 1), 14.4% (2A+2B), 25% (3), 66% (4), and 100% (5). Using analysis of variance, neutrophil count and SII were revealed to be significantly higher in malignant categories ( P <0.05). High SII values correlated strongly with categories 4 and 5, suggesting poor prognosis. Conclusion: The ISRSFC framework effectively stratifies pleural effusion cases with a stepwise increase in ROM, reinforcing its diagnostic reliability. Additionally, the SII provides independent prognostic value, being significantly elevated in malignant categories. Together, the ISRSFC and SII offer a reproducible, low-cost marker for risk assessment and prognosis in pleural effusion patients. Larger multicentric studies are warranted to validate these findings.
- 9 July 2026
- Published by Wolters Kluwer Health in Journal of Cytology
- Vol. 43 (3) , 167-173
Open AccessDiagnostic Efficacy of the International System for Reporting Serous Fluid Cytopathology Classification in Pleural Effusion Samples to Analyze the Risk of Malignancy Associated with Each Category and Explore the Prognostic Significance of the Systemic Immune-Inflammation Index within These Classifications
Background: Pleural effusion is a common clinical manifestation of both neoplastic and nonneoplastic conditions. Cytological evaluation of serous fluids remains a cost-effective and minimally invasive diagnostic tool. To standardize reporting and improve the diagnostic accuracy, the International Academy of Cytopathology and the American Society of Cytopathology proposed the International System for Reporting Serous Fluid Cytopathology (ISRSFC). The Systemic Immune-Inflammation Index (SII) is a composite measure of systemic inflammatory status, being a novel prognostic biomarker. It has been linked to adverse outcomes in several malignancies. This study aimed to evaluate the diagnostic efficacy of the ISRSFC in categorizing pleural effusion samples, determine the risk of malignancy (ROM) for each diagnostic category, and assess the prognostic significance of SII across ISRSFC categories. Materials and Methods: A retrospective cross-sectional study was conducted on 142 pleural effusion cases diagnosed at the All India Institute of Medical Sciences, Rajkot, from January 2023 to April 2025. Cytological samples were classified according to ISRSFC categories and correlated with histopathology, radiology, and clinical data. Complete blood count parameters were retrieved to calculate the SII (neutrophil × platelet/lymphocyte count). Statistical analysis was performed using Statistical Package for the Social Sciences version 23. Results: Of 142 cases, the majority fell into benign categories (2A and 2B, 88%). ROM increased progressively across ISRSFC categories: 0% (Category 1), 14.4% (2A+2B), 25% (3), 66% (4), and 100% (5). Using analysis of variance, neutrophil count and SII were revealed to be significantly higher in malignant categories ( P <0.05). High SII values correlated strongly with categories 4 and 5, suggesting poor prognosis. Conclusion: The ISRSFC framework effectively stratifies pleural effusion cases with a stepwise increase in ROM, reinforcing its diagnostic reliability. Additionally, the SII provides independent prognostic value, being significantly elevated in malignant categories. Together, the ISRSFC and SII offer a reproducible, low-cost marker for risk assessment and prognosis in pleural effusion patients. Larger multicentric studies are warranted to validate these findings.
- Open Access
- 19 June 2026
- Published by Charles University in Prague, Karolinum Press in Prague Medical Report
- Vol. 127 (2) , 137-139
Plasma Cell Vulvitis (Zoon’s Vulvitis): A Rare Case Report with Emphasis on Diagnostic Challenge
Plasma cell vulvitis (PCV), also referred to as Zoon’s vulvitis, is a rare and chronic inflammatory condition of the vulva characterized by distinctive red, glistening patches with a subtle red-orange hue. The condition can be asymptomatic or present with symptoms such as discomfort, dyspareunia, and pruritus, often mimicking other vulvar mucosal disorders like lichen planus. Due to its rarity and the overlap of symptoms with more common vulvovaginal conditions, PCV is frequently underreported and misdiagnosed. The exact etiology of PCV remains unclear, with possible associations to herpes simplex virus (HSV) and abnormal immune responses being hypothesized. This manuscript presents a case of PCV in a 46-year-old female who presented with a red, glistening, focally ulcerated patch on the vulva.
- 19 June 2026
- Published by Charles University in Prague, Karolinum Press in Prague Medical Report
- Vol. 127 (2) , 137-139
Open AccessPlasma Cell Vulvitis (Zoon’s Vulvitis): A Rare Case Report with Emphasis on Diagnostic Challenge
Plasma cell vulvitis (PCV), also referred to as Zoon’s vulvitis, is a rare and chronic inflammatory condition of the vulva characterized by distinctive red, glistening patches with a subtle red-orange hue. The condition can be asymptomatic or present with symptoms such as discomfort, dyspareunia, and pruritus, often mimicking other vulvar mucosal disorders like lichen planus. Due to its rarity and the overlap of symptoms with more common vulvovaginal conditions, PCV is frequently underreported and misdiagnosed. The exact etiology of PCV remains unclear, with possible associations to herpes simplex virus (HSV) and abnormal immune responses being hypothesized. This manuscript presents a case of PCV in a 46-year-old female who presented with a red, glistening, focally ulcerated patch on the vulva.
- 3 April 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (3) , 332-344
Urinary adiponectin as a non-invasive biomarker of renal impairment in type 2 diabetes mellitus: evidence from a cross-sectional study
1. Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease and end-stage renal disease worldwide, and its burden is particularly high in India, where pooled estimates suggest tha...
- 3 April 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (3) , 332-344
Urinary adiponectin as a non-invasive biomarker of renal impairment in type 2 diabetes mellitus: evidence from a cross-sectional study
1. Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease and end-stage renal disease worldwide, and its burden is particularly high in India, where pooled estimates suggest tha...
- 29 December 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 20 (1) , 5-15
Stage-specific association of urinary C-megalin with diabetic kidney disease: a cross-sectional study in type 2 diabetes
This study aimed to evaluate urinary C-megalin in relation to disease staging and diagnostic accuracy in Indian patients with type 2 diabetes mellitus (T2DM). In this cross-sectional study, 325 participants were classified into No-DKD, early-DKD, and late-DKD based on kidney disease improving global outcomes (KDIGO) criteria. Urinary C-megalin was quantified by enzyme-linked immunosorbent assay (ELISA) as absolute and creatinine-normalized values. Group comparisons, correlation analyses, and multinomial logistic regression were performed to assess associations with disease stage. Creatinine-normalized C-megalin excretion was higher in early-DKD compared with No-DKD (median 125.0 vs. 92.0 ng/mg Cr; p = 0.02) and independently associated with early disease [odds ratio (OR) = 1.26, 95% confidence interval (CI): 1.03-1.55; p = 0.02). In late-DKD, absolute C-megalin levels were significantly associated with disease status (OR = 1.23, 95% CI: 1.02-1.48; p = 0.03), while normalized values lost significance. Diagnostic evaluation showed moderate accuracy for detecting early-DKD [area under curve (AUC): 0.69, 95% CI: 0.62-0.76, p = 0.001). Urinary C-megalin demonstrates stage-dependent diagnostic behavior in DKD, suggesting potential as a complementary marker for early tubular injury and advanced disease in high-risk diabetic populations.
- 29 December 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 20 (1) , 5-15
Stage-specific association of urinary C-megalin with diabetic kidney disease: a cross-sectional study in type 2 diabetes
This study aimed to evaluate urinary C-megalin in relation to disease staging and diagnostic accuracy in Indian patients with type 2 diabetes mellitus (T2DM). In this cross-sectional study, 325 participants were classified into No-DKD, early-DKD, and late-DKD based on kidney disease improving global outcomes (KDIGO) criteria. Urinary C-megalin was quantified by enzyme-linked immunosorbent assay (ELISA) as absolute and creatinine-normalized values. Group comparisons, correlation analyses, and multinomial logistic regression were performed to assess associations with disease stage. Creatinine-normalized C-megalin excretion was higher in early-DKD compared with No-DKD (median 125.0 vs. 92.0 ng/mg Cr; p = 0.02) and independently associated with early disease [odds ratio (OR) = 1.26, 95% confidence interval (CI): 1.03-1.55; p = 0.02). In late-DKD, absolute C-megalin levels were significantly associated with disease status (OR = 1.23, 95% CI: 1.02-1.48; p = 0.03), while normalized values lost significance. Diagnostic evaluation showed moderate accuracy for detecting early-DKD [area under curve (AUC): 0.69, 95% CI: 0.62-0.76, p = 0.001). Urinary C-megalin demonstrates stage-dependent diagnostic behavior in DKD, suggesting potential as a complementary marker for early tubular injury and advanced disease in high-risk diabetic populations.
- Open Access
- 1 November 2025
- Published by S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L in Journal of Medicine and Life
- Vol. 18 (11) , 1016-1023
Retrospective study of histomorphological examination of skin lesion biopsies and their clinical concordance: experience from a tertiary care hospital in India
Histopathological examination is a cornerstone in dermatological diagnosis, providing critical insights into the pathogenesis and classification of
- 1 November 2025
- Published by S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L in Journal of Medicine and Life
- Vol. 18 (11) , 1016-1023
Open AccessRetrospective study of histomorphological examination of skin lesion biopsies and their clinical concordance: experience from a tertiary care hospital in India
Histopathological examination is a cornerstone in dermatological diagnosis, providing critical insights into the pathogenesis and classification of
- Open Access
- 18 September 2025
- Published by Charles University in Prague, Karolinum Press in Prague Medical Report
- Vol. 126 (3) , 159-161
Unveiling the Enigma: Plasma Cell Leukaemia Presenting with Flower-like Cells, Mimicking Adult T-cell Leukaemia – A Rare Diagnostic Conundrum
Peripheral plasma cell leukaemia (PCL) is a rare hematologic malignancy that can pose diagnostic challenges due to its resemblance to other conditions such as adult T-cell leukaemia/lymphoma (ATLL) or dissemination lymphoma in peripheral blood. We present a case report of a 40-year-old male with symptoms of fatigue, irregular heartbeat, weight loss, and bone pain, whose peripheral blood examination revealed hyperleukocytosis with atypical lymphoid cells exhibiting flower-shaped nuclei, reminiscent of adult T-cell leukaemia/lymphoma. Further investigations including bone marrow aspiration and biopsy confirmed the diagnosis of primary PCL. Immunophenotyping revealed expression of plasma cell antigens CD38 and CD138. This case underscores the importance of recognizing morphological variants and employing comprehensive immunophenotypic analysis for accurate diagnosis of PCL, especially when atypical nuclear features mimic other hematologic malignancies.
- 18 September 2025
- Published by Charles University in Prague, Karolinum Press in Prague Medical Report
- Vol. 126 (3) , 159-161
Open AccessUnveiling the Enigma: Plasma Cell Leukaemia Presenting with Flower-like Cells, Mimicking Adult T-cell Leukaemia – A Rare Diagnostic Conundrum
Peripheral plasma cell leukaemia (PCL) is a rare hematologic malignancy that can pose diagnostic challenges due to its resemblance to other conditions such as adult T-cell leukaemia/lymphoma (ATLL) or dissemination lymphoma in peripheral blood. We present a case report of a 40-year-old male with symptoms of fatigue, irregular heartbeat, weight loss, and bone pain, whose peripheral blood examination revealed hyperleukocytosis with atypical lymphoid cells exhibiting flower-shaped nuclei, reminiscent of adult T-cell leukaemia/lymphoma. Further investigations including bone marrow aspiration and biopsy confirmed the diagnosis of primary PCL. Immunophenotyping revealed expression of plasma cell antigens CD38 and CD138. This case underscores the importance of recognizing morphological variants and employing comprehensive immunophenotypic analysis for accurate diagnosis of PCL, especially when atypical nuclear features mimic other hematologic malignancies.